BenzingaBenzinga Japan
BenzingaBenzinga Japan
BenzingaBenzinga Japan
金曜日, 9 25

Definium Therapeutics Inc

DFTXNASDAQ
Trade with Public
Trade with Public
$36.73
-0.92-2.44%
近くで: Sep 24, 5:00 PM EST
$36.82
0.090.25%
時間外: 7:45 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Definium Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Definium Therapeutics (DFTX).

Price Target Range — 3 Quarters

Analyst Consensus — 15 Analysts

15Buy
Consensus RatingBuy# Analysts15Avg. Consensus PT$64Upside to Avg. PT+72.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →
DateFirmAnalystActionRating ChangePrice Target
Sep 15, 2026Canaccord GenuitySumant KulkarniPT RaiseBuy$64→$78
Sep 15, 2026Baird Christopher ChenPT RaiseOutperform$75→$79
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Canaccord Genuity Maintains Buy on Definium Therapeutics, Raises Price Target to $78

Canaccord Genuity analyst Sumant Kulkarni maintains Definium Therapeutics (NASDAQ:DFTX) with a Buy and raises the price target from $64 to $78.
Benzinga Newsdesk

PRO
Baird Maintains Outperform on Definium Therapeutics, Raises Price Target to $79

Baird analyst Christopher Chen maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $75 to $79.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Definium Therapeutics, Maintains $70 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $70 price target.
Benzinga Newsdesk

PRO
Needham Reiterates Buy on Definium Therapeutics, Maintains $66 Price Target

Needham analyst Ami Fadia reiterates Definium Therapeutics (NASDAQ:DFTX) with a Buy and maintains $66 price target.
Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Definium Therapeutics, Maintains $66 Price Target

RBC Capital analyst Brian Abrahams reiterates Definium Therapeutics (NASDAQ:DFTX) with a Outperform and maintains $66 price target.
Benzinga Newsdesk

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Top analysts changed outlook on top names. See analyst ratings page for all changes.
Avi Kapoor

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

BenzingaBenzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved